-
Loading metrics
Open Access
Peer-reviewed
Research Article
The selective PI3Kα inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line models
-
Svenja Nölting,
Roles Conceptualization, Data curation, Investigation, Project administration, Writing – original draft, Writing – review & editing
Affiliations Department of Internal Medicine II, Klinikum der Universität München (KUM), Ludwig-Maximilians-Universität München, München, Bavaria, Germany, Department of Internal Medicine IV, Klinikum der Universität München (KUM), Ludwig-Maximilians-Universität München, München, Bavaria, Germany
⨯ -
Jakob Rentsch,
Roles Data curation, Investigation
Affiliation Dept. of Gastroenterology, CC13 (CBF and CVK), Charité - Universitätsmedizin Berlin, Berlin, Germany
⨯ -
Helma Freitag,
Roles Data curation, Investigation
Affiliation Dept. of Gastroenterology, CC13 (CBF and CVK), Charité - Universitätsmedizin Berlin, Berlin, Germany
⨯ -
Katharina Detjen,
Roles Investigation
Affiliation Dept. of Gastroenterology, CC13 (CBF and CVK), Charité - Universitätsmedizin Berlin, Berlin, Germany
⨯ -
Franziska Briest,
Roles Investigation
Affiliations Dept. of Gastroenterology, CC13 (CBF and CVK), Charité - Universitätsmedizin Berlin, Berlin, Germany, Dept. of Gastroenterology and Endocrinology, Zentralklinik Bad Berka GmbH, Bad Berka, Germany, Dept. of Chemistry and Biochemistry, Freie Universität (FU) Berlin, Berlin, Germany
⨯ -
Markus Möbs,
Roles Investigation
Affiliation Institute of Pathology, Charité - Universitätsmedizin Berlin, Berlin, Germany
⨯ -
Victoria Weissmann,
Roles Investigation
Affiliation Department of General, Visceral and Thoracic Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
⨯ -
Britta Siegmund,
Roles Investigation
Affiliation Dept. of Gastroenterology, CC13 (CBF and CVK), Charité - Universitätsmedizin Berlin, Berlin, Germany
⨯ -
Christoph J. Auernhammer,
Roles Investigation
Affiliations Department of Internal Medicine II, Klinikum der Universität München (KUM), Ludwig-Maximilians-Universität München, München, Bavaria, Germany, Department of Internal Medicine IV, Klinikum der Universität München (KUM), Ludwig-Maximilians-Universität München, München, Bavaria, Germany
⨯ -
Elke Tatjana Aristizabal Prada,
Roles Investigation
Affiliation Department of Internal Medicine II, Klinikum der Universität München (KUM), Ludwig-Maximilians-Universität München, München, Bavaria, Germany
⨯ -
Michael Lauseker,
Roles Formal analysis
Affiliation Institute for Medical Information Sciences, Biometry, and Epidemiology, Ludwig-Maximilians-Universität München, München, Bavaria, Germany
⨯ -
Ashley Grossman,
Roles Writing – review & editing
Affiliation Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, United Kingdom and Neuroendocrine Tumour Centre, Royal Free Hospital, London, United Kingdom
⨯ -
Samantha Exner,
Roles Investigation
Affiliation Dept. of Gastroenterology, CC13 (CBF and CVK), Charité - Universitätsmedizin Berlin, Berlin, Germany
⨯ -
Christian Fischer,
Roles Investigation
Affiliation Dept. of Gastroenterology, CC13 (CBF and CVK), Charité - Universitätsmedizin Berlin, Berlin, Germany
⨯ -
Carsten Grötzinger,
Roles Investigation, Writing – original draft
Affiliation Dept. of Gastroenterology, CC13 (CBF and CVK), Charité - Universitätsmedizin Berlin, Berlin, Germany
⨯ -
Jörg Schrader ,
Contributed equally to this work with: Jörg Schrader, Patricia Grabowski
Roles Conceptualization, Funding acquisition, Investigation, Writing – original draft, Writing – review & editing
Affiliations Department of General, Visceral and Thoracic Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, Medical Department I, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
⨯ -
Patricia Grabowski ,
Contributed equally to this work with: Jörg Schrader, Patricia Grabowski
Roles Funding acquisition, Investigation, Project administration, Writing – review & editing
* E-mail: patricia.grabowski@charite.de
Affiliations Dept. of Gastroenterology, CC13 (CBF and CVK), Charité - Universitätsmedizin Berlin, Berlin, Germany, Dept. of Gastroenterology and Endocrinology, Zentralklinik Bad Berka GmbH, Bad Berka, Germany
⨯ - [ ... ],
-
on behalf of the GERMAN NET-Z study group
¶Complete membership of the author group can be found in the Acknowledgments.
⨯ - [ view all ]
- [ view less ]
The selective PI3Kα inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line models
- Svenja Nölting,
- Jakob Rentsch,
- Helma Freitag,
- Katharina Detjen,
- Franziska Briest,
- Markus Möbs,
- Victoria Weissmann,
- Britta Siegmund,
- Christoph J. Auernhammer,
- Elke Tatjana Aristizabal Prada
- Published: August 11, 2017
- https://doi.org/10.1371/journal.pone.0182852